Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Gelderblom

Showing results (81-90 of 488) with videos related to

Pageof 49
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxelHans Gelderblom, Jaap Verweij, Desirée M van Zomeren, et al.
European Journal of Cancer (Oxford, England : 1990)|October 28, 2018
Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse eventsDirk H Wijn, Geert H Groeneveld, Albert M Vollaard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancerVincent O Dezentjé, Henk-Jan Guchelaar, Johan W R Nortier, et al.
Hematology/Oncology Clinics of North America|October 8, 2013
Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcomaJolieke G van Oosterwijk, Jakob K Anninga, Hans Gelderblom, et al.
Cancer Cell|June 11, 2024
Testing dilemmas in the clinic: Lessons learned from biomarker-based drug developmentSahar Barjesteh van Waalwijk van Doorn-Khosrovani, Olga Kholmanskikh Van Criekingen, Simone Koole, et al.
Cancer Biology & Therapy|May 24, 2005
Effect of ABCG2 genotype on the oral bioavailability of topotecanAlex Sparreboom, Walter J Loos, Herman Burger, et al.
Frontiers in Pharmacology|October 29, 2020
Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic ReviewEmma C Hulshof, Lifani Lim, Ignace H J T de Hingh, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2016
Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathwayAnnemiek M van Maldegem, Judith V M G Bovée, Elleke F P Peterse, et al.
Sarcoma|August 2, 2021
Patterns of Perioperative Treatment and Survival of Localized, Resected, Intermediate- or High-Grade Soft Tissue Sarcoma: A 2000-2017 Netherlands Cancer Registry Database AnalysisMilan Van Meekeren, Marta Fiocco, Vincent K Y Ho, et al.
Anti-Cancer Drugs|March 14, 2003
Red blood cells: a neglected compartment in topotecan pharmacokinetic analysisWalter J Loos, Hans Gelderblom, Jaap Verweij, et al.
Pageof 49

Showing results (81-90 of 488) with videos related to

Sort By:
Pageof 49
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxelHans Gelderblom, Jaap Verweij, Desirée M van Zomeren, et al.
European Journal of Cancer (Oxford, England : 1990)|October 28, 2018
Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse eventsDirk H Wijn, Geert H Groeneveld, Albert M Vollaard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancerVincent O Dezentjé, Henk-Jan Guchelaar, Johan W R Nortier, et al.
Hematology/Oncology Clinics of North America|October 8, 2013
Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcomaJolieke G van Oosterwijk, Jakob K Anninga, Hans Gelderblom, et al.
Cancer Cell|June 11, 2024
Testing dilemmas in the clinic: Lessons learned from biomarker-based drug developmentSahar Barjesteh van Waalwijk van Doorn-Khosrovani, Olga Kholmanskikh Van Criekingen, Simone Koole, et al.
Cancer Biology & Therapy|May 24, 2005
Effect of ABCG2 genotype on the oral bioavailability of topotecanAlex Sparreboom, Walter J Loos, Herman Burger, et al.
Frontiers in Pharmacology|October 29, 2020
Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic ReviewEmma C Hulshof, Lifani Lim, Ignace H J T de Hingh, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2016
Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathwayAnnemiek M van Maldegem, Judith V M G Bovée, Elleke F P Peterse, et al.
Sarcoma|August 2, 2021
Patterns of Perioperative Treatment and Survival of Localized, Resected, Intermediate- or High-Grade Soft Tissue Sarcoma: A 2000-2017 Netherlands Cancer Registry Database AnalysisMilan Van Meekeren, Marta Fiocco, Vincent K Y Ho, et al.
Anti-Cancer Drugs|March 14, 2003
Red blood cells: a neglected compartment in topotecan pharmacokinetic analysisWalter J Loos, Hans Gelderblom, Jaap Verweij, et al.
Pageof 49